Table I.
Patient demographics and clinical characteristics (n=94).
| Characteristic | Number of patients, n (%) |
|---|---|
| Median age at enrollment, years (range) | 60 (32–82) |
| Sex | |
| Male | 37 (39.3) |
| Female | 57 (60.7) |
| ECOG PS | |
| 0 | 64 (68.1) |
| 1 | 24 (25.5) |
| 2 | 6 (6.4) |
| Primary site | |
| Right-sided colon | 26 (27.7) |
| Left-sided colon | 68 (72.3) |
| Metastatic site | |
| Lung | 69 (73.4) |
| Liver | 56 (59.6) |
| Lymph node | 46 (48.9) |
| Peritoneal | 40 (42.6) |
| Other | 26 (27.7) |
| RAS status in tissue | |
| Wild-type | 37 (39.4) |
| Mutant | 57 (60.6) |
| Time from the start of first-line chemotherapy, months | |
| <18 | 32 (34.0) |
| ≥18 | 60 (63.8) |
| Unknown | 2 (2.2) |
| Number of prior regimens | |
| 1 | 0 (0.0) |
| 2 | 68 (72.3) |
| 3 | 22 (23.4) |
| 4 | 4 (4.3) |
| Prior regimens | |
| Fluoropyrimidine | 94 (100.0) |
| Irinotecan | 94 (100.0) |
| Oxaliplatin | 93 (98.9) |
| Angiogenesis inhibitor | 94 (100.0) |
| Anti-EGFR antibodies | 18 (19.1) |
| Number of metastasis | |
| 1 | 10 (10.6) |
| >1 | 84 (89.4) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; Other, brain, bone, ovary and adrenal glands; RAS, rat sarcoma viral oncogene homolog; EGFR, epidermal growth factor receptor.